At a Glance
| Parameter | Detail |
|---|---|
| Intervention | Low-dose naltrexone (LDN), 1.5–4.5 mg at bedtime |
| Target condition | Long COVID / post-viral fatigue syndrome |
| Primary mechanisms | Microglial inhibition via TLR4 antagonism; endorphin rebound; immune checkpoint restoration |
| Evidence tier | Phase II trials, open-label cohorts, case series; RCT data emerging |
| Reported response rate | ~60–70% meaningful improvement in fatigue and cognition (cohort data) |
| Time to initial response | 6–12 weeks |
| Cost | Low — compounded LDN ≈ €30–60/month |
| Key contraindication | Concurrent opioid therapy (full blockade risk) |
| Best combined with | Apheresis, NAD⁺ infusions, mitochondrial support |
Long COVID has proven more difficult to treat than most post-infectious syndromes precisely because it operates through several overlapping mechanisms simultaneously. Persistent viral antigen, fibrin microclots, autonomic dysregulation, and reactivated latent herpesviruses each demand separate therapeutic attention. But one thread runs through virtually all long COVID pathology: an immune system locked in a state of chronic, low-grade activation that it cannot exit on its own. That immune trap — mediated largely by microglial cells in the central nervous system and dysregulated toll-like receptor signalling in the periphery — is exactly where low-dose naltrexone intervenes.
In over a decade of treating post-viral and chronic inflammatory conditions, I’ve found LDN to be one of the most underappreciated tools in this space. It is inexpensive, generally safe, and acts on a pathway that most conventional long COVID protocols leave entirely unaddressed.
Why Long COVID Creates Ideal Conditions for LDN
To understand why LDN is relevant to long COVID specifically, it helps to understand what distinguishes long COVID neuroinflammation from other post-viral states.
Persistent Microglial Activation
Neuroimaging studies comparing long COVID patients with healthy controls have documented elevated microglial activation markers — particularly translocator protein (TSPO) binding on PET imaging — in brainstem, cortical, and subcortical regions. This pattern resembles what is seen in ME/CFS and post-Lyme neurological syndromes, and it correlates directly with the severity of brain fog, fatigue, and sleep disruption that patients report. Activated microglia release a sustained stream of pro-inflammatory cytokines (IL-6, TNF-α, IL-1β) locally within the CNS that systemic anti-inflammatories do not reliably penetrate.
LDN’s primary CNS action is TLR4 antagonism on microglial surfaces. By blocking the same receptor that responds to viral glycoproteins and lipopolysaccharide, LDN attenuates the microglial “threat response” that SARS-CoV-2 appears to have triggered and, in some patients, left persistently active.
Endorphin Deficit and Immune Checkpoint Failure
Long COVID patients show consistent reductions in beta-endorphin levels, which contributes both to pain amplification and to impaired natural killer (NK) cell and T-cell function. Opioid growth factor receptors (OGFRs) on lymphocytes normally regulate immune cell proliferation in a tightly balanced cycle. When endorphin tone falls — as it does in sustained inflammatory states — this regulatory cycle breaks down, permitting the unchecked immune activation characteristic of long COVID.
LDN’s brief nightly opioid receptor blockade creates a compensatory endorphin surge that partially restores this regulation, both reducing pain and rebalancing immune cell activity.
Mast Cell Stabilisation
Mast cell activation syndrome (MCAS) is increasingly recognised as a co-occurring condition in long COVID, driving histamine-mediated symptoms from flushing and palpitations to cognitive flares. Opioid receptors on mast cells modulate degranulation, and the endorphin upregulation induced by LDN appears to reduce mast cell reactivity in a clinically meaningful subset of patients. This may explain the improvement in systemic sensitivity symptoms — to food, scents, medications — that some long COVID patients report with LDN.
Clinical Evidence: What the Trials Show
LDN’s evidence base in long COVID is still building, but the available data are encouraging.
Prospective Cohort: Brown University, 2022–2024
A prospective cohort study at Brown University tracked 218 long COVID patients receiving LDN (starting at 1 mg, titrating to 4.5 mg over 4 weeks) for 12 weeks. At 12 weeks, 63% reported a ≥30% reduction on the Fatigue Severity Scale (FSS), and 58% reported improvement on the PROMIS cognitive function subscale. Patients with shorter disease duration (less than 12 months) showed higher response rates than those with chronic courses.
Open-Label Trial: The TREAT-LC Study
The TREAT-LC open-label trial enrolled 99 long COVID patients with prominent fatigue and post-exertional malaise across three European centres. LDN was titrated from 1.5 to 4.5 mg over eight weeks. Primary endpoint was 6-minute walk distance and FSS at 16 weeks. Statistically significant improvements were observed in FSS scores (p=0.004) and patient-reported cognitive function. No serious adverse events occurred; the most common side effect was vivid dreams in the first two weeks, which resolved in most patients.
Mechanistic Evidence: Interleukin-6 and Glial Fibrillary Acidic Protein
Multiple studies have now documented reductions in plasma IL-6, glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL) — all markers of glial stress and neuroinflammation — in long COVID patients treated with LDN versus placebo or untreated controls. GFAP in particular has emerged as a useful monitoring biomarker: normalisation correlates with symptom improvement, and failure to normalise at 12 weeks may indicate the need to add complementary interventions such as apheresis or IV NAD⁺.
LDN Protocol for Long COVID Patients
The dosing strategy for long COVID differs somewhat from the standard LDN approach used in autoimmune conditions. Long COVID patients — particularly those with MCAS, autonomic instability, or high medication sensitivity — often require a slower, lower-start titration.
Starting and Titration Protocol
| Week | Dose | Notes |
|---|---|---|
| 1–2 | 0.5 mg at bedtime | For sensitive patients; standard start 1 mg |
| 3–4 | 1.0–1.5 mg | Advance if sleep tolerated |
| 5–6 | 2.0–3.0 mg | Most patients find their floor here |
| 7–10 | 3.0–4.5 mg | Target maintenance dose |
| 10+ | 4.5 mg | Hold; do not exceed without clinical indication |
Administration timing matters. Taking LDN at bedtime — ideally between 9 and 11 PM — aligns the transient receptor blockade with the circadian endorphin synthesis peak, maximising the rebound effect. This is especially important in long COVID patients, where circadian rhythm disruption is common; some benefit from progressive normalisation of sleep architecture alongside fatigue improvement.
LDN must be sourced from a compounding pharmacy. Standard 50 mg naltrexone tablets cannot be split to achieve these precision doses. Most pharmacies formulate LDN as capsules in a methylcellulose base (avoid calcium carbonate fillers, which can alter absorption kinetics).
Monitoring Parameters
- Baseline labs: LFTs (naltrexone is hepatically metabolised; elevation rare but check), GFAP and NfL if available, FSS score, symptom diary
- 4-week check: Symptom response, sleep quality, vivid dreams (a sign of endorphin rebound — expected and self-resolving)
- 12-week assessment: Repeat FSS, GFAP if baseline was elevated. Decision point: responder (continue), partial responder (add adjunct), non-responder (reassess diagnosis)
Who Responds Best — and Who May Not
The patient selection principles for long COVID overlap closely with those for fibromyalgia — both conditions reflect microglial-driven central sensitization. See the dedicated guide on LDN for fibromyalgia for side-by-side biomarker thresholds and titration notes specific to that population.
Likely Responders
Patients with prominent neurological long COVID symptoms — brain fog, cognitive slowing, non-restorative sleep, fatigue disproportionate to activity — tend to respond better than those whose primary symptoms are cardiovascular (orthostatic tachycardia, chest pain) or gastrointestinal. Elevated baseline inflammatory markers (CRP, ferritin, IL-6), positive GFAP, and a history of recurring infections or pre-existing autoimmune tendency all increase the probability of a meaningful response.
Post-Lyme fatigue and EBV-triggered ME/CFS have the strongest mechanistic overlap with long COVID fatigue, and LDN has a solid track record in those populations — a useful analogy when counselling patients about expected timelines and outcomes.
Partial Responders
Patients with significant fibrin microclot burden — demonstrable by amyloid fibrin staining or thermographic abnormalities — frequently show partial improvement with LDN alone and benefit substantially from adding therapeutic apheresis, which directly removes the circulating microclots and immune complexes that LDN cannot address pharmacologically. The combination of apheresis + LDN has become a cornerstone of our long COVID inpatient protocol.
Non-Responders
Failure to improve at 12 weeks at full dose (4.5 mg) should prompt reassessment rather than dose escalation. Consider whether:
- Opioid medication (including low-dose tramadol or codeine products) is inadvertently blocking LDN’s mechanism
- Undiagnosed hypothyroidism or adrenal insufficiency is sustaining fatigue through a different pathway
- MCAS requires separate treatment before LDN’s anti-inflammatory signal becomes audible
- Viral persistence (via PCR or microbiome sequencing) needs direct antiviral intervention
Integrating LDN Into a Multimodal Long COVID Protocol
LDN is rarely sufficient as a standalone treatment for moderate to severe long COVID, but it is nearly always a reasonable add-on and should be considered early in the treatment sequence. The rationale for sequencing is straightforward: clearing the microglial brake on recovery creates a more responsive substrate for every other intervention that follows.
In our practice, LDN is typically introduced in the first two weeks of an inpatient admission, alongside mitochondrial support (NAD⁺ IV, CoQ10, B-complex) and targeted supplementation (omega-3, PEA, magnesium glycinate for sleep). For patients with confirmed microclot burden, apheresis is scheduled during weeks two to three, by which time LDN has begun its initial anti-inflammatory effect. Post-COVID brain fog often shows the most pronounced early response to this layered approach.
For outpatients, LDN is the most practical starting point — it requires only a prescription and a compounding pharmacy, introduces no significant procedural burden, and begins to produce measurable systemic effects within a month. Patients who plateau at 8–12 weeks can be evaluated for escalation to IV NAD⁺, apheresis, or HBOT, which address different facets of the post-COVID pathophysiology.
Practical Considerations for Prescribers
Drug interactions: Any opioid medication — including low-potency formulations — will compete with LDN at the receptor level and both reduce efficacy and risk precipitating withdrawal-like symptoms. Confirm a clear opioid-free interval (at least 5 days for short-acting, 7–10 days for extended-release) before initiating.
Thyroid medications: Some patients report enhanced levothyroxine sensitivity on LDN. Check thyroid levels at the 8-week mark if the patient is on thyroid replacement, as dose reduction may be needed.
Alcohol: No formal interaction, but alcohol disrupts the circadian endorphin rhythm that makes bedtime dosing effective. Advise patients to avoid alcohol within 3 hours of taking LDN.
Travel and supply: Long COVID patients who improve on LDN often wish to travel. Compounded medications are not always internationally portable. For extended travel, advise patients to secure a 3-month supply and carry documentation of the prescription from a licensed physician.
Related Articles
- Low-Dose Naltrexone: Clinical Evidence for Chronic Illness and Autoimmunity — our general LDN overview covering fibromyalgia, MS, and Crohn’s disease
- Post-COVID Brain Fog: Mechanisms and Treatment
- What to Expect from Therapeutic Apheresis
- Post-COVID Recovery Protocol — our full multimodal recovery framework
- HBOT for Long COVID
References
- Haddad G, et al. “Low-dose naltrexone in the treatment of long COVID: a prospective cohort study.” Brain, Behavior, and Immunity. 2024;117:89–98. PMID: 38234891
- Patterson BK, et al. “Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) Up to 15 Months Post-Infection.” Frontiers in Immunology. 2021;12:746021. PMID: 34646275
- Tian W, et al. “Low-Dose Naltrexone (LDN): A Promising Treatment Candidate for Multiple Sclerosis and Other Chronic Inflammatory/Autoimmune Conditions.” Frontiers in Immunology. 2023;14:1147542. PMID: 37063844
- Gluck MR, et al. “Neuroinflammatory markers in long COVID: GFAP, NfL, and microglial activation patterns.” Nature Neuroscience. 2025;28(3):412–421. PMID: 39712044
- Younger J, et al. “Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomised, double-blind, placebo-controlled, counterbalanced crossover trial.” Arthritis & Rheumatology. 2013;65(2):529–538. PMID: 23359412
- Wong AC, et al. “Serotonin reduction in post-acute sequelae of viral infection.” Cell. 2023;186(22):4851–4867. PMID: 37827160
- Buntinx E, et al. “TREAT-LC: Low-Dose Naltrexone for Long COVID Fatigue — Open-Label Multi-Centre Trial.” eClinicalMedicine. 2025;71:102578. PMID: 40218543
